We claim:

1. A composition comprising an antibody drug conjugate for use in the treatment of cancer, wherein the cancer is follicular lymphoma (FL) that expresses CCR7, in a subject in need thereof, wherein the antibody drug conjugate comprises the formula

$$Ab—(L—(D)_m)_n$$

or a pharmaceutically acceptable salt thereof; wherein
Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;
L is a linker;
D is a drug moiety;
m is an integer from 1 to 8; and
n is an integer from 1 to 12.


2. Use of an antibody drug conjugate in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, wherein the cancer is follicular lymphoma (FL) that expresses CCR7, wherein the antibody drug conjugate comprises the formula

$$Ab—(L—(D)_m)_n$$

or a pharmaceutically acceptable salt thereof; wherein
Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;
L is a linker;
D is a drug moiety;
m is an integer from 1 to 8; and
n is an integer from 1 to 12.

3. The composition for use of claim 1, or the use of claim 2, wherein the cancer is relapsed or refractory follicular lymphoma.

4. The composition for use of claim 1 or claim 3, or the use of claim 2 or claim 3, where in the antibody drug conjugate comprises the following formula:



wherein n is about 3 to about 4, and Ab is an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:47, and a light chain comprising the amino acid sequence of SEQ ID NO:63; or a pharmaceutically acceptable salt thereof.

5. The composition for use of any one of claims 1, or 3-4, or the use of any one of claims 2-4, where in the antibody drug conjugate is in a non-salt form.

6. The composition for use of any one of claims 1, or 3-5, or the use of any one of claims 2-5, wherein the antibody drug conjugate or composition is to be administered to the patient in combination with one or more additional therapeutic compounds.

7. The composition for use or the use of claim 6, wherein the one or more additional therapeutic compounds is selected from a standard of care chemotherapeutic, a costimulatory molecule, or a checkpoint inhibitor.

8. The composition for use or the use of claim 7, wherein the costimulatory molecule is selected from an agonist of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, STING, or CD83 ligand.

9. The composition for use or the use of claim 7, wherein the checkpoint inhibitor is selected from an inhibitor of PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and/or TGFR beta.

10. A composition comprising an antibody drug conjugate for use in the treatment of cancer, wherein the cancer expresses CCR7, in a subject in need thereof, wherein the antibody drug conjugate comprises the formula

$$Ab—(L—(D)_m)_n$$

or a pharmaceutically acceptable salt thereof; wherein
Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;
L is a linker;
D is a drug moiety;
m is an integer from 1 to 8; and
n is an integer from 1 to 12,


wherein the antibody drug conjugate is to be administered to said subject at about 0.1 mg/kg to about 10 mg/kg.

11. Use of an antibody drug conjugate in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, wherein the cancer expresses CCR7, wherein the antibody drug conjugate comprises the formula

$$Ab—(L—(D)_m)_n$$

or a pharmaceutically acceptable salt thereof; wherein
Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;
L is a linker;
D is a drug moiety;
m is an integer from 1 to 8; and
n is an integer from 1 to 12,
wherein the antibody drug conjugate is to be administered to said subject at about 0.1 mg/kg to about 10 mg/kg.

12. The composition for use of claim 10 or the use of claim 11, where in the antibody drug conjugate comprises the following formula:



wherein n is about 3 to about 4, and Ab is an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:47, and a light chain comprising the amino acid sequence of SEQ ID NO:63; or a pharmaceutically acceptable salt thereof.

13. The composition for use of claim 10 or claim 12, or the use of claims 11 or claim 12, where in the antibody drug conjugate is in a non-salt form.

14. The composition for use of any one of claims 10, or 12-13, or the use of any one of claims 11-13, wherein the cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), peripheral T cell lymphomas (PTCL) such as adult T-cell leukemia/lymphoma (ATLL) and anaplastic large-cell lymphoma (ALCL), Non-Hodgkin's lymphoma (NHL) such as mantle cell lymphoma (MCL), Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL), and non-small cell lung cancer.

15. The composition for use of any one of claims 10, or 12-14, or the use of any one of claims 11-14, wherein the cancer is a relapsed or refractory cancer.

16. The composition for use of any one of claims 10, or 12-15, or the use of any one of claims 11-15, wherein the antibody drug conjugate is to be administered to the subject about once every 3 weeks.

17. The composition for use of any one of claims 10, or 12-16, or the use of any one of claims 11-16, wherein the subject is to be treated for 1 cycle, 2 cycles, 3 cycles, 4 cycles, or 5 cycles.

18. The composition for use of any one of claims 10, or 12-17, or the use of any one of claims 11-17, wherein the antibody drug conjugate is to be administered to the subject intravenously.